Programa de Pós-Graduação em Ciências Farmacêuticas - PPGCF/ICS
URI Permanente desta comunidadehttps://repositorio.ufpa.br/handle/2011/2312
O Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF) vinculado ao Instituto de Ciências da Saúde (ICS) da Universidade Federal do Pará (UFPA) apresenta um auto-impacto de inserção regional uma vez que se trata do único PPGCF na Região Norte pelo grande potencial de utilização da biodiversidade na região amazônica. Além de favorecer a fixação e atração de profissionais qualificados na área de Ciências Farmacêuticas na Região Amazônica.
Navegar
Navegando Programa de Pós-Graduação em Ciências Farmacêuticas - PPGCF/ICS por CNPq "CNPQ::CIENCIAS DA SAUDE::SAUDE COLETIVA::SAUDE PUBLICA"
Agora exibindo 1 - 3 de 3
- Resultados por página
- Opções de Ordenação
Item Acesso aberto (Open Access) Adesão ao tratamento da malária vivax em crianças(Universidade Federal do Pará, 2016-04-01) SANTOS, José Alberto Gomes dos; ANDRADE, Marcieni Ataíde de; http://lattes.cnpq.br/8514584872100128Malaria is an infectious disease endemic in 104 countries and vivax malaria accept responsibility for 25 to 40% of the global burden of disease worldwide. The South America has high transmission rates shown by the annual parasite incidence (API) greater than 1% of the population. In recent years it has been observed in Brazil the prevalence of infection with P. vivax. The treatment protocol isased on the combination of chloroquine and primaquine, however, treatment failures have been reported worldwide including in Brazil with adherence as one of the causes. Several factors can interfere in the adherence between them: education, sex, absence of signs and symptoms and socioeconomic profile. This study evaluated the adherence to malaria treatment from determining the profile demographic partner of children with vivax malaria in Anajás and determined the plasma concentrations of chloroquine and primaquine of the study patients. For the profile of the participants was used questionnaire was complete source of information. To measure adherence to treatment was used indirect test Morisky-Green assessing the patient's attitude towards treatment. The plasma concentration of primaquine and its metabolite was made by collecting paper filter venous blood on day D1 and D7 and determined HPLC. The profile of patients showed that most of the children were male, with the primary caregiver mother, education and income were considered low, despite the distribution the use of mosquito nets it is irregular, 92.4% of households have no sewage system, and 33.3% use water from the river for consumption .The indirect test Morisky- Green classified 42 children as adherent and 08 as no adherent The plasma concentration of PQ in D7 adherent and no adherent were related and showed no significant difference, since the CPQ concentrations in D7 Adherent showed statistically significant result, with higher values in adherent patients.Item Acesso aberto (Open Access) Avaliação da adesão ao tratamento preconizado para malária: determinação da primaquina em pacientes diagnosticados com Plasmodium vivax(Universidade Federal do Pará, 2016-03-31) GONÇALVES FILHO, Wilson Vieira; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098; ANDRADE, Marcieni Ataíde de; http://lattes.cnpq.br/8514584872100128Malaria is a disease that threatens 50% of the world population living in endemic areas such as Africa, Asia and Latin America. Concerning malaria caused by Plasmodium vivax in Brazil, which treatment is based on primaquine and chloroquine, it is a major public health issue that hinders the development of the Amazon region and adherence to drug therapy is one of the main factors that influence the effectiveness of the drug. This study uses indirect methods assess treatment adherence, correlating it with plasma concentrations of primaquine and carboxyprimaquine. Thus, a cross-sectional observational controlled study was conducted with 27 patients in Anajás, Pará before (D0), during (D1) and after (D7) treatment using the antimalarials, followed by the assessment of the patients with questions based on Morisky-Green test at the end of the treatment. Higher prevalence of vivax malaria was observed in males (70.4%) and age group of 20-39 years (55.56%), Morisky-Green test indicated adherence of 75%, 15 out of 20 patients, with hit rates of 80%, 65%, 70% and 65% to the questions. Mean-value of primaquine concentration on D1 was 134.8 ng/mL, and 131.9 ng/mL on D7, values for carboxyprimaquine are 408 ng/ml and 529.4 ng/mL respectively. It is possible to observe a statistically significant difference in the carboxyprimaquine values between D1 and D7 in the acceding group defined by the Morisky-Green tests, showing that carboxyprimaquine accumulates in the body; therefore being more suitable for assessing adherence to treatment. Therefore, it is important to point out these concentrations of primaquine and carboxyprimaquine consist as the first determination study of drugs and metabolites found for the short-course treatment suggested by the Ministry of Health for vivax malaria in the Amazon region, supporting the studies of adherence surveys regarding antimalarials.Item Acesso aberto (Open Access) Monitoramento das reações adversas ao novo tratamento da tuberculose(Universidade Federal do Pará, 2016-05-22) RODRIGUES, Miguel Wanzeller; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098Tuberculosis is an infectious disease that despite the effective prophylactic and therapeutic resources is one of the most serious problems of global public health. In 2014, there were 67,966 new cases of the disease in Brazil, with the highest incidence rate in the states of Amazonas, Rio de Janeiro, Acre, Pernambuco, Mato Grosso and Pará. Three factors contribute to continuity of tuberculosis in Brazil: the HIV pandemic the development of multiresistant strains and failure of BCG. The lack of adherence to treatment is one of the main reasons the spread of resistance. In order to reduce this problem and minimize adverse reactions, WHO in 2006 recommended a new regimen: 2RHZE (intensive phase) and 4R (maintenance phase), which was adopted by Brazil in 2010. However, adverse reactions requiring discontinuation of treatment has not been estimated with the new regimen, which justifies this study aimed to analyze the occurrence of adverse events in subjects with tuberculosis in the use of new treatment regimen (Isoniazid, Rifampin, Ethambutol, Pyrazinamide). A prospective longitudinal study of 57 subjects with clinical diagnosis, laboratory and radiological tuberculosis. The renal function tests (urea and creatinine) and liver (AST, ALT, alkaline phosphatase, bilirubin and gamma GT) were performed every month of treatment. In the study, Disease affected more males with low education, who used tobacco and alcohol and regardless of age. There were increasing urea values in the last two months of treatment, but creatinine was normal during treatment. Regarding the assessment of liver function, fluctuations were observed in biochemical parameters analyzed, but remained in the normal range. It is noteworthy that a subject has developed framework of cholestatic liver disease, which resolved upon discontinuation of treatment. Early diagnosis, coupled with immediate treatment enables the patient an effective outcome in the fight against tuberculosis, as it keeps the biochemical parameters without major changes, allowing for a better adherence and clinical improvement of the patient.